Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population‐based propensity‐weighted cohort study

AIMS: Acenocoumarol is a vitamin‐K antagonist (VKA) primarily used in certain countries (e.g. India, Netherlands, Spain). The half‐life of acenocoumarol is similar to that of non‐VKA oral anticoagulants (NOAC), unlike warfarin, and this could affect comparative effectiveness and safety (CES). Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez‐Bernal, Clara L., Santa‐Ana‐Téllez, Yared, García‐Sempere, Aníbal, Hurtado, Isabel, Peiró, Salvador, Sanfélix‐Gimeno, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328430/
https://www.ncbi.nlm.nih.gov/pubmed/32530052
http://dx.doi.org/10.1111/bcp.14430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328430/
https://www.ncbi.nlm.nih.gov/pubmed/32530052
http://dx.doi.org/10.1111/bcp.14430

Ejemplares similares